Cancer Letters
Volume 220, Issue 1 , Pages 85-93 , 18 March 2005

Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors

  • Tomonori Takahashi

      Affiliations

    • Department of Molecular Biology, Faculty of Medicine, Toho University, 5-21-16 Ohmori-Nishi, Ohta-Ku, Tokyo 143-8540, Japan
    • ,
  • Zhenghua Min

      Affiliations

    • Department of Molecular Biology, Faculty of Medicine, Toho University, 5-21-16 Ohmori-Nishi, Ohta-Ku, Tokyo 143-8540, Japan
    • ,
  • Iichiro Uchida

      Affiliations

    • Department of Molecular Biology, Faculty of Medicine, Toho University, 5-21-16 Ohmori-Nishi, Ohta-Ku, Tokyo 143-8540, Japan
    • ,
  • Michitsune Arita

      Affiliations

    • Department of Molecular Biology, Faculty of Medicine, Toho University, 5-21-16 Ohmori-Nishi, Ohta-Ku, Tokyo 143-8540, Japan
    • ,
  • Yoh Watanabe

      Affiliations

    • Department of Obstetrics and Gynecology, Kinki University School of Medicine, Osaka, Japan
    • ,
  • Minoru Koi

      Affiliations

    • Department of Biological Sciences, Brunel Institute of Cancer Genetics and Pharmacogenomics, Brunel University, Uxbridge, Middlesex, UK
    • ,
  • Hiromichi Hemmi

      Affiliations

    • Department of Molecular Biology, Faculty of Medicine, Toho University, 5-21-16 Ohmori-Nishi, Ohta-Ku, Tokyo 143-8540, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 3 3762 4151; fax: +81 3 3764 6923.

Received 9 June 2004 ,Accepted 15 July 2004.

References 

  1. Loeb A. Cancer cells exhibit a mutator phenotype. Adv. Cancer Res. 1998;72:25–56
  2. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816–819
  3. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 1995;55:6063–6070
  4. Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JKV, et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene. 1995;10:33–37
  5. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutations. Cancer Res. 1994;54:4308–4312
  6. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 1995;55:3721–3725
  7. Risinger JI, Umar A, Boyd J, Berchuck A, Kunkel TA, Barrett JC. Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Nat. Genet. 1996;14:102–105
  8. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 1997;57:3949–3955
  9. Watanabe Y, Haugen-Strano A, Umar A, Yamada K, Hemmi H, Kikuchi Y, et al. Complementation of an hMSH2-defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol. Carcinog. 2000;29:37–49
  10. Fink D, Nebel S, Norris PS, Aebi S, Kim HK, Haas M, et al. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells. Br. J. Cancer. 1998;77:703–708
  11. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087–3090
  12. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 1996;271:19645–19648
  13. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117:123–131
  14. Uchida I, Zhong X. Differential cytotoxicity of anticancer agents in hMutSα-deficient and -proficient human colorectal cancer cells. Tissue Cult. Res. Commun. 1999;18:301–312
  15. Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 1997;3:1763–1767
  16. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int. J. Cancer. 2001;93:571–576
  17. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 1981;41:1751–1756
  18. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003;349:247–257
  19. Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br. J. Cancer. 2001;85:1064–1069
  20. Rashbaum SA, Cozzarelli NR. Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine. Nature. 1976;264:679–680
  21. Tanaka M, Yoshida S, Kimura K. Mechanism of inhibition of DNA polymerases by 4′-epiadriamycin and 4′-O-tetrahydropyranyladriamycin. Gann. 1983;74:829–836
  22. David JC, Bassez T, Bonhommet M, Rusquet R. Inhibition of DNA ligase from human thymocytes and normal or leukemic lymphocytes by antileukemic drugs. Cancer Res. 1985;45:2177–2183
  23. Oguro M, Suzuki-Hori C, Nagano H, Mano Y, Ikegami S. The mode of inhibitory action by aphidicolin on eukaryotic DNA polymerase α. Eur. J. Biochem. 1979;97:603–607
  24. Muller WE, Rohde HJ, Beyer R, Maidhof A, Lachmann M, Taschner H, et al. Mode of action of 9-β-d-arabinofuranosyladenine on the synthesis of DNA, RNA, and protein in vivo and in vitro. Cancer Res. 1975;35:2160–2168
  25. Maruo N, Horiuchi H, Nakabo T, Kondo M, Nakamura T. Cytokinetic study on the effects of N4-behenoyl-1-β-d-arabinofuranosylcytosine on murine leukemic cells L1210: A comparison with the effects of 1-β-d-arabinofuranosylcytosine. Hematol. Oncol. 1985;3:39–48
  26. Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem. Biophys. Res. Commun. 1968;33:129–135
  27. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110–6117
  28. Burris HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl Cancer Inst. 1992;84:1816–1820
  29. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990;50:1715–1720
  30. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187–4191
  31. Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother. Pharmacol. 2002;49:438–444
  32. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000;256:42–49
  33. Brown KD, Rathi A, Kamath R, Beardsley DI, Zhan Q, Mannino JL, et al. The mismatch repair system is required for S-phase checkpoint activation. Nat. Genet. 2003;33:80–84
  34. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 2000;14:927–939

PII: S0304-3835(04)00636-6

doi: 10.1016/j.canlet.2004.07.044

Cancer Letters
Volume 220, Issue 1 , Pages 85-93 , 18 March 2005

Article Tools

* Image Usage & Resolution